awmsg logo



aflibercept (Eylea®)


Reference No. 1721

Publication date:
30/06/2015


Appraisal information

aflibercept (Eylea®) 40 mg/ml solution for injection


Company: Bayer Healthcare Pharmaceuticals
BNF category: Eye
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Superseded
Advice No: Not available
Ratification by Welsh Government: 26/06/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA409) NICE GUIDANCE ISSUED OCTOBER 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) In the absence of a submission from the holder of the marketing authorisation, aflibercept (Eylea®) cannot be endorsed for use within NHS Wales for the treatment of adults with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO).
Statement of Advice (SOA)
Download